Watters, James

EMT is the dominant program in human colon cancer

Loboda, A., Nebozhyn, M. V., Watters, J. W., Buser, C. A., Shaw, P. M., Huang, P. S., Van't Veer, L., Tollenaar, R. A., Jackson, D. B., Agrawal, D., et al. (2011) · BMC Medical Genomics

Gene expression and cancer classificationCancer Cells and Metastasis

Cited by 274

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 152

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics

Glioma Diagnosis and TreatmentBarrier Structure and Function Studies

Cited by 39

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

Williams, B., Taylor, A., Orozco, O., Owen, C., Kelley, E., Lescarbeau, A., Shortsleeves, K., Kipp, R., Nguyen, V., Brophy, E., et al. (2022) · Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 7